Stock OJU1 ORAMED PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Market Closed - Deutsche Boerse AG
Other stock markets
 07:04:45 10/05/2024 BST 		5-day change 1st Jan Change
2.186 EUR -1.44% Intraday chart for Oramed Pharmaceuticals Inc. +1.11% +4.54%
05-09 Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-19 Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oramed: Q1 Earnings Snapshot
AQ
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction
PU
Oramed Pharmaceuticals : 13D-Nadav Kidron
PU
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction
PU
Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024
CI
Oramed Pharmaceuticals : Other Report or Announcement
PU
Oramed Pharmaceuticals : Other Report or Announcement
PU
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Oramed Pharmaceuticals Inc. Announces Resignation of Yadin Rozov from the Board of Directors
CI
Oramed Pharmaceuticals : Other Report or Announcement
PU
Oramed Pharmaceuticals : Other Report or Announcement
PU
Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024
CI
Oramed Pharmaceuticals : Form 8-K - Director Appointment- Dr. Daniel Aghion, effective as of January 1, 2024.
PU
Oramed: Q3 Earnings Snapshot
AQ
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Oramed Pharmaceuticals Inc.(TASE:ORMP) dropped from TA-125 Index
CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics
MT
Scilex Holding Company announced that it has received $101.875 million in funding from Oramed Pharmaceuticals Inc.
CI
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORMP Stock
  4. OJU1 Stock
  5. News Oramed Pharmaceuticals Inc.